Abstract
The SARS-CoV-encoded papain-like cysteine protease (PLpro) plays crucial roles in viral replication and maturation processes. It is required to cleave the precursor polyproteins into functional proteins. Thus, it is considered to be a promising target for developing specific drugs. For rational optimization of hit compounds, information about the structure-activity relationship (SAR) is fundamental. Herein, we characterize isoindolines as a new class of PLpro inhibitors.
The content is available as a PDF (437.3 KB).
Footnotes
Funding note
Open Access funding enabled and organized by Projekt DEAL.
Stefan Josef Hammerschmidt 2011–2015 Pharmaziestudium, Universität Mainz. 2016 Approbation als Apotheker. Seit 2018 Promotion im Bereich der Pharmazeutischen/Medizinischen Chemie am Institut für Pharmazeutische und Biomedizinische Wissenschaften (IPBW), Mainz.
Patrick Müller 2013–2019 Studium der Biomedizinischen Chemie an der Universität Mainz. Seit 2020 Promotion im Bereich der Pharmazeutischen/Medizinischen Chemie am Institut für Pharmazeutische und Biomedizinische Wissenschaften (IPBW), Mainz.
Tanja Schirmeister 1988 Approbation als Apothekerin. 1989–1999 Promotion und anschließend Habilitation im Fach Pharmazeutische/Medizinische Chemie. 2000 Hochschuldozentin (C2) am Pharmazeutischen Institut der Universität Freiburg. 2000–2011 C3-Professur für Pharmazeutische/Medizinische Chemie, Universität Würzburg. Seit 2011 Universitätsprofessorin (W3) für Pharmazeutische/Medizinische Chemie, Universität Mainz.
Literatur
- [1].Welker A, Kersten C, Müller C, et al. Structure-activity relationships of benzamides and isoindolines designed as SARS-CoV protease inhibitors effective against SARS-CoV-2. ChemMedChem. 2021;16:340–354. doi: 10.1002/cmdc.202000548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [2].Amendola G, Ettari R, Previti S et al. (2021) Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening. J Chem Inf Model, 10.1021/acs.jcim.1c00184 [DOI] [PubMed]
- [3].Shin D, Mukherjee R, Grewe D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587:657–662. doi: 10.1038/s41586-020-2601-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].Ratia K, Pegan S, Takayama J, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci. 2008;105:16119–16124. doi: 10.1073/pnas.0805240105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5].Ghosh A, Takayama J, Rao K, et al. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-Ray structure and biological evaluation. J Med Chem. 2010;53:4968–4979. doi: 10.1021/jm1004489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].Báez-Santos Y, Barraza, Wilson M, et al. X-Ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J Med Chem. 2014;57:2393–2412. doi: 10.1021/jm401712t. [DOI] [PMC free article] [PubMed] [Google Scholar]